To include your compound in the COVID-19 Resource Center, submit it here.

Innate's KIR royale

BMS adds immunotherapy arm with Innate's anti-KIR mAb for cancer

With a product on the market that harnesses the adaptive immune system to attack cancer, Bristol-Myers Squibb Co. made its first move into the innate immunology space by licensing a mAb from Innate Pharma S.A. that stimulates NK cell activity.

The candidate, IPH 2102, is in a Phase I trial for acute myelogenous leukemia.

On the adaptive front, FDA approved BMS's Yervoy ipilimumab in April to treat metastatic melanoma. The mAb against

Read the full 708 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers